(2R,3R,4S,5S,6R)-3-hexoxy-6-(hydroxymethyl)oxane-2,4,5-triol

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (2R,3R,4S,5S,6R)-3-hexoxy-6-(hydroxymethyl)oxane-2,4,5-triol
• 化学式: C₁₂H₂₄O₆
• 分子量: 264.31
• InChiKey: VLNFUWOINJTHRB-RMPHRYRLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  18
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  99.4
• 氢给体数：
  4
• 氢受体数：
  6

文献信息

• PROCESS FOR STRAIGHTENING KERATIN FIBRES WITH A HEATING MEANS AND DENATURING AGENTS
  申请人：Philippe Michel

  公开号：US20100028280A1

  公开（公告）日：2010-02-04

  The invention relates to a process for straightening keratin fibres, comprising: (i) a step in which a straightening composition containing at least two denaturing agents is applied to the keratin fibres, (ii) a step in which the temperature of the keratin fibres is raised, using a heating means, to a temperature of between 110 and 250° C.

  该发明涉及一种直发角蛋白纤维的拉直过程，包括：(i)将至少两种变性剂含有的拉直组合物涂抹到角蛋白纤维上的步骤，(ii)使用加热装置将角蛋白纤维的温度升高至110至250°C的步骤。
• Methods and compositions for gene delivery
  申请人：——

  公开号：US20030134420A1

  公开（公告）日：2003-07-17

  The present invention provides novel compositions and formulations for delivering anionic compounds, particularly polynucleotides (DNA and RNA), across cellular boundaries (e.g., cellular membranes) either in vivo or in vitro.

  本发明提供了用于递送阴离子化合物的新型组合物和配方，特别是多核苷酸（DNA和RNA），跨越细胞边界（例如细胞膜）的方法，无论是在体内还是体外。
• Porous drug matrices and methods of manufacture thereof
  申请人：Acusphere Inc.

  公开号：US20020142050A1

  公开（公告）日：2002-10-03

  Drugs, especially low aqueous solubility drugs, are provided in a porous matrix form, preferably microparticles, which enhances dissolution of the drug in aqueous media. The drug matrices preferably are made using a process that includes (i) dissolving a drug, preferably a drug having low aqueous solubility, in a volatile solvent to form a drug solution, (ii) combining at least one pore forming agent with the drug solution to form an emulsion, suspension, or second solution and hydrophilic or hydrophobic excipients that stabilize the drug and inhibit crystallization, and (iii) removing the volatile solvent and pore forming agent from the emulsion, suspension, or second solution to yield the porous matrix of drug. Hydrophobic or hydrophilic excipients may be selected to stabilize the drug in crystalline form by inhibiting crystal growth or to stabilize the drug in amorphous form by preventing crystallization. The pore forming agent can be either a volatile liquid that is immiscible with the drug solvent or a volatile solid compound, preferably a volatile salt. In a preferred embodiment, spray drying is used to remove the solvents and the pore forming agent. The resulting porous matrix has a faster rate of dissolution following administration to a patient, as compared to non-porous matrix forms of the drug. In a preferred embodiment, microparticles of the porous drug matrix are reconstituted with an aqueous medium and administered parenterally, or processed using standard techniques into tablets or capsules for oral administration.

  药物，特别是低水溶性药物，以多孔性矩阵形式提供，最好是微粒，这可以增强药物在水性介质中的溶解。药物矩阵最好是使用包括以下步骤的过程制备的：(i)将药物，最好是低水溶性药物，溶解在挥发性溶剂中形成药物溶液，(ii)将至少一种孔形成剂与药物溶液结合形成乳液、悬浮液或第二溶液和亲水或疏水的赋形剂，以稳定药物并抑制结晶，(iii)从乳液、悬浮液或第二溶液中除去挥发性溶剂和孔形成剂，以得到多孔性的药物矩阵。亲水或疏水的赋形剂可以被选择用于通过抑制晶体生长来稳定药物的晶体形式，或者用于通过防止结晶来稳定药物的非晶形式。孔形成剂可以是与药物溶剂不相溶的挥发性液体或挥发性固体化合物，最好是挥发性盐。在一个优选实施例中，喷雾干燥用于除去溶剂和孔形成剂。所得到的多孔性矩阵在给患者治疗后具有更快的溶解速率，与非多孔性药物矩阵形式相比。在一个优选实施例中，多孔性药物矩阵的微粒被重组与水性介质，并通过标准技术处理成口服片剂或胶囊剂进行口服给药。
• Injectable Formulation
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：US20150086632A1

  公开（公告）日：2015-03-26

  An object of the present invention is to provide a sustained-release injectable preparation which is in a medication administration form that can provide the effect of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one for a prolonged period of time, the preparation releasing a therapeutically effective amount of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one for at least one week. The present invention provides an injectable preparation containing 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-3H-quinolin-2-one or a salt thereof as an active ingredient, which releases the active ingredient in such a manner that its blood concentration is maintained for at least one week.

  本发明的目的是提供一种持续释放的注射制剂，该制剂以药物给药形式提供7-[4-(4-苯并[b]噻吩-4-基哌嗪-1-基)丁氧基]-1H-喹啉-2-酮的效果，并在至少一周的时间内释放治疗有效量的7-[4-(4-苯并[b]噻吩-4-基哌嗪-1-基)丁氧基]-1H-喹啉-2-酮。本发明提供一种注射制剂，其包含7-[4-(4-苯并[b]噻吩-4-基哌嗪-1-基)丁氧基]-3H-喹啉-2-酮或其盐作为活性成分，以这种方式释放活性成分，使其血浓度至少维持一周。
• Methods for producing nanoparticles
  申请人：Macosko W. Christopher

  公开号：US20070122440A1

  公开（公告）日：2007-05-31

  The present invention relates to methods of preparing nanoparticles from reactively formed block and/or graft copolymers and nanoparticles derived therefrom

  本发明涉及从反应形成的嵌段和/或接枝共聚物中制备纳米粒子的方法及由此得到的纳米粒子。